Jump to main content

TAKHZYRO (lanadelumab-flyo) is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 2 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 2 years of age.

Site search icon.
Mobile navigation icon.

TAKHZYRO (lanadelumab-flyo) is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 2 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 2 years of age.

How is HAE impacting your child?

The onset of hereditary angioedema (HAE) symptoms can occur at any age, but studies suggest symptoms may start to appear during childhood. If you’re living with HAE, or caring for someone with HAE, you know the condition can be:

  • Unpredictable
  • Debilitating
  • Life-threatening (throat attacks)

Potentially fatal throat swells have been reported in patients as young as 3 years old. Young children may be at increased risk if a throat swell occurs, due to their airways being smaller.

TAKHZYRO is a preventive treatment option for your child that offers the possibility of fewer HAE attacks.

Use of TAKHZYRO in children 2 to <12 years old was supported by efficacy data from the 6.5-month study in people ≥12 years old and additional data that showed similar levels of TAKHZYRO were reached in the body for adults and children.

LEARN ABOUT TAKHZYRO FOR CHILDREN

Learn more about TAKHZYRO for children in this informative webinar

WATCH NOW

Has your child recently received an HAE diagnosis? Or are you expanding their current treatment plan? There's support available.

EXPLORE FAMILY RESOURCES

View Transcript

Educate yourself, be prepared, remember there's a community of support out there—hear more thoughts and advice from fellow caregivers.

BOBBI: For other caregivers dealing with HAE, I think the biggest thing you could do is just be supportive and try to understand even if you don't truly understand what that person is going through. But just be there, and love them through it.

JASON: My advice to a new caregiver is to ask a lot of questions, get a lot of answers, and don't be scared to ask questions. There's a lot of people out there that can help, have answers, that they have gone through in their life. It may help them out.

PAM: I would tell caregivers first of all, if you don't have HAE, is to find out about it, to-to know what's going on, and what things need to be done because sometimes those attacks can be an emergency or a life-threatening situation. So, you need to be prepared about what needs to happen for the person who is having the attack. And then I think it's to be sensitive to what's going on with them, to find out or look for clues as to when they might be having attacks coming on, and they may not even recognize it themselves.

JUAN: What I would like say to other caregivers is don't lose hope. There is support out there. There is help out there, and there's a community of people that have gone through the same exact situation that you are in, and there are people that you can talk to.

NARRATOR: What is TAKHZYRO? TAKHZYRO® (lanadelumab) is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 2 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 2 years of age.

NARRATOR: TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms: wheezing, difficulty breathing, chest tightness, fast heartbeat, faintness, rash, hives. The most common side effects seen with TAKHZYRO were injection site reactions (pain, redness, and bruising), upper respiratory infection, headache, rash, dizziness, diarrhea, and muscle aches. These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist.

NARRATOR: You may report side effects to FDA at 1-800-FDA-1088. TAKHZYRO has not been studied in pregnant or breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed. Talk to your healthcare provider about TAKHZYRO, the only preventive HAE treatment you take as a subcutaneous injection just once every two weeks.

Questions about caring for children with HAE?

The US Hereditary Angioedema Association (HAEA) offers advice for parents and caregivers, as well as resources and connections to youth programs. Remember to talk to your doctor about any questions involving your child’s treatment.

Keep Learning

Do you know about the 2 main types of HAE treatment?

DISCOVER THE TYPES
logo

Attend an in-person or virtual event to meet others with HAE and hear from healthcare professionals.

FIND EVENTS